A New Denosumab Biosimilar Just Got FDA Approval. Here Is What It Means for Your Prolia Coverage.

If you take Prolia for osteoporosis, bone loss from cancer treatment, or any related condition, you are going to want to read this. On March 30, 2026, the FDA approved Ponlimsi (denosumab-adet), the first biosimilar to Prolia, manufactured by Teva Pharmaceutical. The approval covers every indication that Prolia is already approved for.

This is not a crisis. But it is a shift that could affect your coverage, your out-of-pocket costs, and your next prescription fill. Here is what is actually happening and what you can do to stay ahead of it.

What Is Prolia, and Who Takes It?

Prolia (denosumab) is a biologic medication given as a subcutaneous injection every six months. It works by blocking a protein called RANK ligand, which plays a key role in bone breakdown. By inhibiting that process, denosumab helps slow bone loss and reduce the risk of fractures.

You may have been prescribed Prolia for one of several conditions:

Postmenopausal osteoporosis at high risk for fracture

Osteoporosis in men at high risk for fracture

Glucocorticoid-induced osteoporosis in men and women on long-term steroids

Bone loss from aromatase inhibitor therapy, which is a class of medications used for breast cancer

Bone loss from androgen deprivation therapy, used for prostate cancer

Prolia is one of the most widely prescribed specialty medications in the country. For Amgen, the drug's manufacturer, it represents more than $7 billion in annual revenue. That scale is exactly why biosimilar competition was inevitable.

The Coverage Reality: What Insurers Will Do Next

Here is the part that directly affects you. Your insurer does not wait for the interchangeable designation to start steering you toward a biosimilar.

Insurers and pharmacy benefit managers routinely update their formularies when lower-cost alternatives become available. We saw this pattern play out extensively with adalimumab biosimilars over the past two years. Many commercial plans moved the original brand to a non-preferred tier or added a step therapy requirement.

The same pattern is likely to unfold with Prolia and Ponlimsi. You may receive a formulary change notice from your insurer, or you may not notice anything until your refill is due and your pharmacist calls with a coverage question.

Ellen can help you understand biosimilar coverage changes and appeal when your doctor believes you should stay on the original medication. Start here →